Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [14892]

Exercise is medicine for cancer and every dose counts - even in late stages in the disease

Exercise is medicine for cancer and every dose counts - even in late stages in the disease

Highlighting the molecular mechanism underlying pancreatic cancer development

Highlighting the molecular mechanism underlying pancreatic cancer development

A double bind for cancer

A double bind for cancer

ASH 2022: Next-generation targeted therapy zanubrutinib found superior to ibrutinib for CLL and SLL

ASH 2022: Next-generation targeted therapy zanubrutinib found superior to ibrutinib for CLL and SLL

Palbociclib combination in advanced breast cancer: Again only disadvantages

Palbociclib combination in advanced breast cancer: Again only disadvantages

ASH 2022: Venetoclax with CLIA highly effective in younger patients with newly diagnosed AML and high-risk MDS

ASH 2022: Venetoclax with CLIA highly effective in younger patients with newly diagnosed AML and high-risk MDS

ASH 2022: Chemotherapy-free regimen ponatinib plus blinatumomab effective in patients with newly diagnosed Ph+ ALL

ASH 2022: Chemotherapy-free regimen ponatinib plus blinatumomab effective in patients with newly diagnosed Ph+ ALL

ASH 2022: Older or high-risk patients with newly diagnosed AML respond well to triplet therapy

ASH 2022: Older or high-risk patients with newly diagnosed AML respond well to triplet therapy

ASH 2022: New data for talquetamab, a first-in-class GPRC5DxCD3 bispecific antibody, suggesting durable responses in patients with heavily pretreated multiple myeloma

ASH 2022: New data for talquetamab, a first-in-class GPRC5DxCD3 bispecific antibody, suggesting durable responses...

ASH 2022: Novel drug shows early promise in treating multiple myeloma

ASH 2022: Novel drug shows early promise in treating multiple myeloma

More from ecancer